A highly powerful nonspecific strategy to reduce COVID-19 deaths

Ji-Ming Chen¹ | Guo-Hui Li¹ | Yu-Fei Ji¹ | Ming-Hui Sun¹ | Huan-Yu Gong¹ | Rui-Xu Chen¹ | Ji-Wang Chen²

¹School of Life Science and Engineering, Foshan University, Foshan, China
²Division of Pulmonary, Critical Care, Sleep, and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

Correspondence
Ji-Ming Chen, School of Life Science and Engineering, Foshan University, Foshan, 528225, China.
Email: jmchen@fosu.edu.cn
Ji-Wang Chen, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Email: chenjw@uic.edu

Funding information
Foshan University

Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the coronavirus severe acute respiratory syndrome coronavirus 2 remains risky worldwide. We elucidate here that good IDM (isolation, disinfection, and maintenance of health) is powerful to reduce COVID-19 deaths based on the striking differences in COVID-19 case fatality rates among various scenarios. IDM means keeping COVID-19 cases away from each other and from other people, disinfecting their living environments, and maintaining their health through good nutrition, rest, and treatment of symptoms and pre-existing diseases (not through specific antiviral therapy). Good IDM could reduce COVID-19 deaths by more than 85% in 2020 and more than 99% in 2022. This is consistent with the fact that good IDM can minimize co-infections and maintain body functions and the fact that COVID-19 has become less pathogenic (this fact was supported with three novel data in this report). Although IDM has been frequently implemented worldwide to some degree, IDM has not been highlighted sufficiently. Good IDM is relative, nonspecific, flexible, and feasible in many countries, and can reduce deaths of some other relatively mild infectious diseases. IDM, vaccines, and antivirals aid each other to reduce COVID-19 deaths. The IDM concept and strategy can aid people to improve their health behavior and fight against COVID-19 and future pandemics worldwide.

KEYWORDS
case fatality rate, co-infection, COVID-19, pandemic, SARS-CoV-2, strategy

1 | INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to 6.32 million deaths worldwide and remains risky to many people worldwide.¹² Unlike in 2020, now COVID-19 vaccines and specific antivirals, such as Molnupiravir and Paxlovid, can all reduce dramatically COVID-19 severe cases and deaths.¹² We elucidate here another strategy that is highly effective to reduce COVID-19 deaths. This strategy is termed IDM (isolation, disinfection, and maintenance of health), which means keeping COVID-19 cases away from each other and from other people, disinfecting their living environments, and maintaining their health through good nutrition, good rest, and treatment of symptoms and pre-existing diseases.
without specific effective antivirals. IDM covers various non-pharmaceutical interventions and pharmaceutical interventions.

In principle, good IDM can reduce COVID-19 deaths because it can minimize co-infections and maintain body functions to fight against various diseases. It has been found that co-infection with influenza and other pathogens increased substantially COVID-19 case fatality rates (CFRs), and shortage of medical services (e.g., providing with ventilators) to maintain the health of COVID-19 cases accounted for vast COVID-19 deaths.\(^4\)

IDM has been implemented worldwide to some degree and its principle is comprehensible, but the integration of isolation of COVID-19 cases, disinfection of their living environments, and maintenance of their health into the IDM concept is new. Moreover, it remains unknown about the effectiveness of IDM to reduce COVID-19 deaths and IDM has not been highlighted sufficiently.

Numerous COVID-19 cases in many countries or regions outside mainland China (MC) could go out to meet other people, live in rooms without disinfection, or be too poor to maintain their health. By contrast, to block completely COVID-19 transmission in MC which has stuck to the strict zero-COVID policy since January 2020, each COVID-19 case in MC was usually separated in a single room with good disinfection and good health maintenance, except in the following two scenarios. One was in Hubei province before June 2020 because too many severe COVID-19 cases in Hubei in that period led to shortage of medical services. The other was in Shanghai in April 2022 because too many asymptomatic or mild COVID-19 cases in the city in that period had to live together in temporary hospitals to separate them from uninfected people, which created co-infection opportunities and led to poor maintenance of health for elders with comorbidities (Figure 1).\(^5\) For example, on April 26, 2022, around 45,000 asymptomatic or mild COVID-19 cases including approximately 6500 elders aged ≥70 lived in the same temporary hospital established from National Convention and Exhibition Center (Shanghai). Some elders with comorbidities encountered difficulties in this temporary hospital.\(^9\) Of the first 65,000 people infected with COVID-19 discharged from this temporary hospital, 20 became severe cases due to aggravation of their comorbidities, and none became severe cases due to viral pneumonia caused by SARS-CoV-2.\(^9\)

Together, the world created 13 scenarios in four groups with different IDM to fight COVID-19 (Figure 2), which could be employed to investigate the effectiveness of IDM to reduce COVID-19 deaths.

## RESULTS

Figure 2A showed that in 2022 the average age of the first 590 COVID-19 deaths in MC (588 in Shanghai and 2 in Jilin) was 83.0, 5.5 years higher than the life expectancy 77.5 in MC in 2020.\(^11\) All these 590 people died directly of their severe comorbidities rather than COVID-19.\(^5\) By contrast, in 2020, the average age of the first 1023 COVID-19 deaths in MC was estimated to be 70.3, and 32.8% of them were originally healthy without comorbidities (Figure 2B).\(^10\) These data suggest SARS-CoV-2 has been much less pathogenic in 2022, which is consistent with previous reports.\(^2\)

Figure 2C showed that COVID-19 CFR was strikingly higher in all the scenarios with worse IDM (p < 0.01, by Chi-square test). COVID-19 CFR was higher by 297 times in Shanghai than in other regions of MC from March 1 to May 31, 2022, by 46–145 times higher in various countries or regions than in MC from June 1, 2020 to April 7, 2022, and by 7 times in Hubei province than in other provinces of MC before June, 2020. Consistent with Figure 1, COVID-19 CFR in Shanghai was 0.000% from March 2 to April 15, 2022, 1.449% from April 15, 2022 to April 30, 2022, and then 0.689% in 05/2022. These striking differences in COVID-19 CFRs all support that good IDM is highly effective to reduce COVID-19 deaths. Meanwhile, the CFR in MC with good IDM was higher by 238 times in 2020 (0.824%) than in 2022 (0.0035%) (Figure 2C), which further supported that COVID-19 has become less pathogenic in 2022.

Good IDM could reduce COVID-19 deaths by more than 99% in 2022 from the COVID-19 CFRs of Shanghai in March and April of 2022 (0.000% versus 1.449%) and by more than 85% in 2020 from...
the COVID-19 CFRs in MC before June 2020 (6.622% versus 0.824%) (Figure 2C).

4 | DISCUSSION

MC has successfully maintained its strict zero-COVID policy from January 2020. To block completely COVID-19 transmission, all the people infected with COVID-19 in MC were identified and their recent traveling histories were published as soon as possible, and their outcomes of recovery or death were known to many people. Therefore, the reported data of COVID-19 infections, cases, recoveries, and deaths in MC were all reliable and nearly equal to their truth values. An analysis suggested that, besides MC, COVID-19 data of Japan, France, Germany, and the United States were also relatively reliable, so their CFRs were employed in this study (Figure 2).13

Various factors, such as data quality, case definition, country, region, city, climate, pollution, virus evolution, human race, smoking, drinking, vaccination coverage, population youngness, or medications, could account partially for some striking differences in COVID-19 CFRS listed in Figure 2.14,15 None of them could account for all the above striking differences, and none of them could account for the COVID-19 CFR differences in the same city of Shanghai between the three adjacent periods (Figures 1 and 2), except IDM. Meanwhile, we created the IDM concept because we cannot differentiate the effectiveness of the three parts of IDM to reduce COVID-19 deaths through these striking differences in COVID-19 CFRs.

In principle, good IDM is more effective to reduce deaths of mild infectious diseases (e.g., influenza) than to reduce deaths of highly pathogenic infectious diseases (e.g., rabies). This is consistent with the above results that good IDM was more effective to reduce COVID-19 deaths in 2022 than in 2020 and that COVID-19 has become less pathogenic in 2022 than in 2020.

Good IDM is more crucial to those unvaccinated elders with comorbidities than to others because these elders are the most vulnerable to COVID-19 infection. Good IDM is more crucial in the regions or periods with co-circulation of influenza, respiratory syncytial virus, or another respiratory pathogen than in other regions or periods.

Good IDM is usually relatively good. For example, in isolation, staying at home is better than shopping which is better than dancing in a crowded room for hours. In disinfection, well-disinfected rooms are better than clean rooms without disinfection which is better than dirty rooms.

Good IDM is flexible, and various behavior or measures belong to good IDM if they have the same functions of IDM in minimizing co-infections and maintaining body functions. For example, walking out for a while with social distancing belongs to good IDM for mild cases. Vaccination for influenza can be an important IDM measure for COVID-19 and has been shown highly effective to reduce COVID-19 deaths in young people in an influenza season in Qatar,16 likely
because influenza vaccination can minimize co-infection of COVID-19 cases with influenza.

Good IDM is nonspecific and can reduce deaths of other mild infectious diseases. Therefore, one can manage good IDM in his home after he has shown influenza-like symptoms without clear diagnosis. Good IDM is hence feasible in many countries with or without mass COVID-19 detection capacity. Meanwhile, good IDM is usually less costly for acute self-limited infectious diseases (e.g., influenza and COVID-19) than for chronic infectious diseases (e.g., hepatitis B and AIDs).

Usually, mild cases can manage good IDM in their homes because their health is relatively easy to be well maintained. Severe cases can usually obtain good IDM in hospitals, although patients in some hospitals may also encounter poor IDM if the hospitals are full of patients and nosocomial infections are not well controlled.

Good IDM is significantly affected by many factors such as healthy policies, regulations, education, culture, economics, and individual behavior (e.g., smoking and exercising). Therefore, the guidance of good IDM can be different for different countries, regions, and individuals. Usually, people have to balance good IDM versus freedom, legal rights, and economy.

IDM can explain some elusive phenomena, such as the above striking and elusive differences in COVID-19 CFRs and the high effectiveness of influenza vaccination to reduce COVID-19 deaths. Moreover, good IDM is feasible and flexible in many countries to reduce deaths of relatively mild infectious diseases. The IDM concept and strategy can aid people to improve their health behavior and defeat COVID-19 and future pandemics.

Nonspecific good IDM, specific effective vaccines, and specific effective antivirals aid each other to reduce COVID-19 deaths. They work on different targets (Figure 3). Those who are qualified in health for vaccination should be vaccinated with COVID-19 vaccines in time, and all vaccinated or unvaccinated people should manage good IDM for themselves if they have influenza-like symptoms, and severe COVID-19 cases, no matter whether they have been vaccinated or obtained good IDM, should be treated with effective antivirals, if possible. Importantly, we should not just rely on good IDM to reduce the severity of rables and other highly pathogenic infectious diseases. Meanwhile, some basic IDM measures (e.g., timely hand washing, avoiding being too tired or cold, and treatment of diabetes and other chronic diseases) should be considered to avoid various infections and maintain health (Figure 3).

5 | CONCLUSION

We calculated multiple striking differences in COVID-19 CFRs in various scenarios. These differences support that good IDM is highly powerful to reduce COVID-19 deaths. Good IDM could reduce COVID-19 deaths by more than 85% in 2020 and more than 99% in 2022. This is consistent with the theoretic functions of good IDM and the fact that COVID-19 has been less pathogenic. Good IDM is relative, nonspecific, flexible, and feasible in many countries, and can reduce deaths of some other relatively mild infectious diseases. IDM, vaccines, and antivirals aid each other to reduce COVID-19 deaths, and they cannot replace each other. The IDM concept and strategy can aid people to improve their health behavior and fight against COVID-19 and future pandemics worldwide.

AUTHOR CONTRIBUTIONS

Ji-Ming Chen conceived, designed, and supported this study, analyzed the data, and drafted the manuscript. Ji-Wang Chen made the core conclusion. All authors collected relevant data and revised the manuscript.

ACKNOWLEDGMENTS

The authors thank deeply all the people who produced, collected, organized, visualized, and shared the COVID-19 data that constituted the vital basis of this study. This study was supported by the High-Level Talent Fund of Foshan University (no. 20210036). The funder did not play any role in this study.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data supporting the views of this analysis are available from the corresponding author on request.

REFERENCES

1. Worldometer. Coronavirus. Accessed on June 4, 2022. https://www.worldometers.info/coronavirus/
countries
2. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update. Accessed on June 4, 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
3. Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses. J Med Virol. 2021;93(4):2385-2395. doi:10.1002/jmv.26740
4. Adelman D. Thousands of lives could be saved in the US during the COVID-19 pandemic if states exchanged ventilators. Health Aff (Millwood). 2020;39(7):1247-1252. doi:10.1377/hlthaff.2020.00505
5. National Health Commission of China. COVID-19 information. Accessed on June 4, 2022. http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml
6. Health Commission of Hubei Province. Dynamic important information. Accessed on June 4, 2022. https://wjw.hubei.gov.cn/bmdt/dtyw/
7. Shanghai Municipal Health Commission. Press releases. Accessed on June 4, 2022. https://wjswj.sh.gov.cn/xwfb/index.html
8. Normile D. China refuses to end harsh lockdowns. Science. 2022;376(6591):333-334. doi:10.1126/science.abq6109
9. Chen E COVID-19 infections in Shanghai is declining. Accessed on June 4, 2022. https://www.sohu.com/a/541561233_121345914
10. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19). China CDC Weekly. 2020;2:113-122.
11. United Nations. 2019 Revision of World Population Prospects. Accessed on June 4, 2022. https://population.un.org/wpp/
12. Suryawanshi RK, Chen IP, Ma T, et al. Limited cross-variant immunity from SARS-CoV-2 omicron without vaccination. Nature. 2022. doi:10.1038/s41586-022-04865-0
13. Farhadi N. Can we rely on COVID-19 data? An assessment of data from over 200 countries worldwide. Sci Prog. 2021;104(2):368504211021232. doi:10.1177/00368504211021232
14. Abou Ghayda R, Lee KH, Han YJ, et al. The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta-analysis. J Med Virol. 2022;94:2402-2413. doi:10.1002/jmv.27610
15. Zhang F, Karamagi H, Nsenga N, et al. Predictors of COVID-19 epidemics in countries of the world health organization African region. Nat Med. 2021;27:2041-2047. doi:10.1038/s41591-021-01491-7
16. Chen JM, Chen YQ. China can prepare to end its zero-COVID policy. Nat Med. 2022;28:1104-1105. doi:10.1038/s41591-022-01794-3
17. Callaway E. Flu vaccine could cut COVID risk. Nature. 2022; 605(7911):602. doi:10.1038/d41586-022-01315-9
18. Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 omicron in China. Nat Med. 2022; doi:10.1038/s41591-022-01855-7

How to cite this article: Chen J-M, Li G-H, Ji Y-F, et al. A highly powerful non-specific strategy to reduce COVID-19 deaths. J Med Virol. 2022;94:5051-5055. doi:10.1002/jmv.27949